A recent meta-analysis evaluating the efficacy of first- and second-line treatment in older metastatic renal cell carcinoma (mRCC) patients (65 years or older) and comparing efficacy between older and younger (less than 65 years) patients, reports that the majority of first-line treatments are not as effective in older patients.

The data suggest that a combination of the immunotherapies nivolumab plus ipilimumab is the most effective treatment for older patients, and cabozantinib is probably the most effective therapy for older patients in the second-line setting. This sequence of treatments offers the best survival outcomes for older patients with mRCC.

Read more in Practice Update here